Literature DB >> 3529518

Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations.

T Zysset, T Zeugin.   

Abstract

The Amicon Centrifree micropartition system was compared with the Sartorius SM 13249E Centrisart I ultrafiltration device to determine non-protein-bound phenytoin levels. Phenytoin was measured by an enzyme multiplied immunoassay technique (EMIT), adapted to a Cobas Bio centrifugal analyzer, and by a radiometric assay. From pooled human plasma with total phenytoin concentrations of 19.1, 44.0, and 95.1 microM, the following percentages of free phenytoin levels in the ultrafiltrate were obtained with Amicon: 10.6 +/- 1.3, 10.5 +/- 0.4, and 8.8 +/- 0.2. The corresponding figures with Sartorius were 5.4 +/- 0.8, 5.4 +/- 0.5, and 4.9 +/- 0.4, respectively (n = 5). Similar results were obtained with 3H-labeled phenytoin, ruling out the possibility that the discrepancies were due to interference with the EMIT assay. Phenytoin binding to the Amicon membrane was less than or equal to 5% of the free phenytoin concentration, whereas the Sartorius membranes absorbed 80%. With the Amicon device, the free phenytoin concentration remained constant as serial ultrafiltrate volumes from the same sample were collected, whereas with Sartorius, free phenytoin increased from 2.5 +/- 1.8% of the total concentration in the first fraction to 13.4 +/- 1.6% in the last collection (n = 6). The results indicate that the Amicon Centrifree filter is an excellent tool to obtain protein-free phenytoin ultrafiltrates, whereas the Sartorius Centrisart I device is not suited for this purpose because of excessive adsorption of phenytoin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529518     DOI: 10.1097/00007691-198609000-00019

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.

Authors:  J Sennesael; D Verbeelen; L Vanhaelst; R Pirola; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers.

Authors:  E K Hussey; G E Dukes; J A Messenheimer; K L Brouwer; K H Donn; T F Krol; L J Hak
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

Review 3.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

4.  Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam.

Authors:  S R Bareggi; R Pirola; P Potvin; G Devis
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function.

Authors:  J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.